Prof. Jacob gives an overview of new antidiabetic interventions that showed a reduction in CV and total mortality in CV risk patients, which seems to be independent of improved glycemic control.
This lecture was part of a CME accredited symposium: "Targeting SGLT2 in clinical cardiology: Exploring the benefits in CV Risk, Diabetes & Heart failure" during ESC 2018 in Munich, Germany.
Prof Stephan Jacob , MD - endocrinologist/diabetologist, University of Tübingen and Cardio Metabolic Institute, Villingen-Schwenningen, Germany
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- Targeting SGLT2 in Clinical Cardiology: Exploring the Benefits in CV risk, Diabetes & Heart FailureSGLT2 inhibition in cardiology: What is the profile of benefit?
Nikolaus Marx, MD